 SOUTH SAN FRANCISCO, Calif., March 18, 2021 PRNewswire -- Sutro Biopharma, Inc. NASDAQ: STRO, a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today reported its financial results for the year ended December 31, 2020, its recent business highlights, and provided a preview of anticipated selected milestones in 2021. 